BRING THIS TO YOUR DOCTOR · GREY PEPTIDES

Palopegteriparatide

Also called: Yorvipath; TransCon PTH

What it is

A once-daily prodrug that releases PTH(1-34) steadily, replacing the hormone itself in adults with hypoparathyroidism rather than only its effects. Approved as Yorvipath; the dose is set by blood calcium, up to 30 micrograms a day.

Approval status

FDA Approved. Approved in the US as Yorvipath (palopegteriparatide injection), NDA 216490, approved August 9, 2024, for hypoparathyroidism in adults (Drugs@FDA via openFDA and the Yorvipath label, read October 2, 2026).

Dosing, as printed in the page's Recommended Dosing box

Manufacturer's recommended dosing (FDA label)

From the prescribing information. Other doses studied, if any, are in the full dosing data below.

Protocol and source	Dose	Frequency	Duration	Route
Label: hypoparathyroidism in adults (calcium at least 7.8 mg/dL and normal vitamin D before starting) **[Approved label]** YORVIPATH (palopegteriparatide) injection Prescribing Information, sections 1, 2, 5, 6 and 12 (DailyMed version 9, effective August 12, 2026)	Start 18 µg; adjust in 3 µg steps to a maximum of 30 µg	Once daily, as a single injection	Ongoing; calcium checked every 4 to 6 weeks once stable	Subcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 11 human studies carded on the page (11 study cards in all):

- **PaTH Forward: phase 2, 59 adults** (Human, 2022). Adults with hypoparathyroidism took 15, 18 or 21 µg a day or placebo for four weeks, then an adjusted dose of 6 to 60 µg a day. By week 26, 91% of those on the drug no longer needed active vitamin D and took 500 mg or less of calcium a day. **PMID 34347093**
- **PaTHway: phase 3, 26 weeks, 84 adults** (Human, 2023). Adults were randomized three to one to the drug, starting at 18 µg a day, or placebo. At week 26, 79% on the drug met the composite primary goal, which required normal blood calcium, against 5% on placebo; 93% no longer needed conventional therapy. Adverse events: 82% against 100%, mostly mild or moderate. **PMID 36271471**
- **PaTHway at one year** (Human, 2025). Of 82 adults who received the drug, 78 completed week 52. At week 52, 81% had normal blood calcium without conventional therapy, 95% were independent of conventional therapy, and none needed active vitamin D. **PMID 39376010**

Interactions

A PubMed search for interaction studies of this compound with any drug (October 6, 2026, 0 records) found none in people. That is not evidence that it is safe to combine with anything.

Side effects and cautions

Reported side effects	Contraindications and cautions
• Adverse events were common in both groups in PaTHway, 82% on the drug and 100% on placebo, mostly mild or moderate • A case report describes a rebound effect after stopping the drug	• A previous severe allergic reaction: the label says to stop permanently • Two injections to make up one dose, which makes the delivered dose more variable • Use without regular blood calcium checks: serious high and low calcium have occurred • Tested athletes — see the Sport (WADA) row below

Five questions to ask

1. Is Palopegteriparatide right for me, and is the labelled dose on this sheet right for my weight, age, kidney and liver function?
2. Here are the medicines and supplements I take. Do any of them interact with Palopegteriparatide? This sheet records none published, which does not mean none exist.
3. Which side effects should make me stop and call you, for example adverse events were common in both groups in pathway?
4. Do any of the cautions on this sheet apply to me, such as: A previous severe allergic reaction: the label says to stop permanently?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.